Time of onset of action of acrivastine in the skin of pollen‐allergic subjects: A double‐blind, randomized, placebo‐controlled comparative study
Research output: Contribution to journal › Journal article › Research › peer-review
The purpose of this study was to assess the time of onset of action of acrivastine in suppressing the wheal response to histamine (10 mg/ml) and allergen (10000 and 100000 BU/ml) in the skin prick test. Ten subjects with a well‐documented allergy to pollen received single doses of 8 mg of acrivastine and placebo according to a randomized, double‐blind, placebo‐controlled, crossover treatment design. Duplicate skin prick tests were performed 0, 15, 20, 25, 30, and 60 min after medication. The results demonstrated a statistically significant suppression of the wheal reactions 15–20 min after medication, depending on the reaction producers used. The sum of all three producers showed a statistically significant effect on the wheal reaction 15 min after medication. The upper 95% confidence limit for time lag from dosing of acrivastine until reduction from placebo level commences was 6.5 min. The study substantiates that orally administered acrivastine has a rapid onset of action in the skin of allergic subjects. The results indicate that allergen SPT is a more sensitive tool for studying antihistaminergic activity than histamine SPT.
Original language | English |
---|---|
Journal | Allergy |
Volume | 49 |
Issue number | 1 |
Pages (from-to) | 27-30 |
Number of pages | 4 |
ISSN | 0105-4538 |
DOIs | |
Publication status | Published - Jan 1994 |
- allergens, human, diagnostic use, histamine, histamine H‐receptor blockers, histamine liberation, drug effects, pharmacology, pyridines, therapeutic use, tripolidine, analogs and derivatives, urticaria, chemically induced
Research areas
ID: 328569512